No matches
Dermatology

Clarifying CSU: Separating Facts From Misconceptions

Dr. Walter Liszewski sheds light on chronic spontaneous urticaria by untangling widespread misconceptions.
Walter Liszewski
MD
Walter Liszewski

Related resources

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Bullous Pemphigoid Mechanism of Disease Video

Bullous Pemphigoid Mechanism of Disease Video

videoanimation
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Infographic
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

expert video
What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregiver

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

expert video
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Scratching the Surface: Understanding Itch in Prurigo Nodularis

Scratching the Surface: Understanding Itch in Prurigo Nodularis

expert video
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

expert video
Diagnosis and Clinical Manifestations of Bullous Pemphigoid

Diagnosis and Clinical Manifestations of Bullous Pemphigoid

expert video
Unmet Needs in Bullous Pemphigoid

Unmet Needs in Bullous Pemphigoid

expert video
Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

expert video
Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

expert video
Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
Inside the Hive: ​Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: ​Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
The Clinical Presentation of CSU is Heterogeneous

The Clinical Presentation of CSU is Heterogeneous

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
KOL Video Interview – Dr. Eric Simpson

KOL Video Interview – Dr. Eric Simpson

expert video
Persistence of AD From Childhood Into Adulthood

Persistence of AD From Childhood Into Adulthood

expert video
Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

slide presentation
KOL Video Interview – Dr Amy Paller

KOL Video Interview – Dr Amy Paller

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Paula Luna

expert video
The Chronic Nature of CSU: Understanding Disease Duration and Persistence

The Chronic Nature of CSU: Understanding Disease Duration and Persistence

expert video
The Role of IL-4 and IL-13 in the Pathophysiology of CSU

The Role of IL-4 and IL-13 in the Pathophysiology of CSU

expert video
Diagnosing CSU: Hives, Angioedema, and Differential Diagnosis

Diagnosing CSU: Hives, Angioedema, and Differential Diagnosis

expert video
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

expert video
Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

expert video
Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation

Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation

expert video
Expert Interview with Dr Jason Hawkes

Expert Interview with Dr Jason Hawkes

expert video
Clinical Assessment of Prurigo Nodularis

Clinical Assessment of Prurigo Nodularis

expert video

Learning objectives

  • Reevaluate common assumptions about the diagnosis, disease burden, and underlying pathophysiology of CSU
Tags
type 2 inflammationchronic pruritusPathophysiologypatient burdenIL-4IL-13mast cells
MAT-US-2610190 v1.0 - P 09/2026

About this expert

Dermatology

Walter Liszewski

MD

Associate Professor of Dermatology and Cancer Epidemiology at Northwestern University, with over six years of experience as a general dermatologist and specialist in patch testing.

See author’s profile
Walter Liszewski

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region